NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review (UPDATED)
Benzinga
The National Institutes of Health (NIH) has discontinued the low-dose rivaroxaban arm of its Phase 3 CAPTIVA stroke prevention trial following an independent safety review that identified increased safety events and evidence the treatment was unlikely to provide benefit. Study sites have been instructed to stop the drug for participants in that arm.
Continue Reading